Metoprolol
As of the edition of 20 October 2026, Metoprolol is a small molecule: marketed, first approved in 1979 (ES); acts on ADRB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Lopressor
- First approved
- 1 January 1979 (ES)
- Approvals on record
- 27 in 3 regions
- Holder of the most recent approval
- Xtm Consulting; 9 holders in all
- Registered trials
- 149, 21 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Nutrition and metabolism; Hormones; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | P08588 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 34 | 17 | 5 | 5 |
| Phase 1 | 42 | 37 | 0 | 4 |
| Phase 2 | 13 | 9 | 0 | 2 |
| Phase 3 | 16 | 7 | 2 | 5 |
| Phase 4 | 44 | 24 | 4 | 5 |
| All trials | 149 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astra | Later holder | 1992 to now |
| AstraZeneca | Later holder and Lead sponsor of trials | 2000 to now |
| Novartis | Acquired holder | 2003 to now |
| SUN Pharmaceutical Industries | Later holder | 2018 to now |
| Validus Pharmaceuticals | Acquired holder | 2021 to now |
| Rubicon | Later holder | 2025 to now |
| Xtm Consulting | Later holder | 2025 to now |
| Melinta Therapeutics Llc A Wholly Owned Sub Of Cormedix | Acquired holder | 2026 to now |
| GEIGY Pharmaceuticals | Earlier holder |